Poly Medicure Ltd. Share Price

Pharma Machtech 2026: India’s Healthcare & FTA Vision

Addressing the Pharma Machtech and Labnext Expo 2026 in New Delhi, Union Minister of Commerce and Industry Piyush Goyal called for India to leverage its status as the "pharmacy of the world" to establish itself as a comprehensive global medical destination. He emphasized that the sector must broaden its focus beyond traditional therapeutics to encompass wellness, diagnostics, medical technology, digital health, and R&D. Urging industry leaders to take full advantage of India’s expanding trade network, Mr. Goyal noted that pre-2014 Free Trade Agreements (FTAs) covered economies with a combined GDP of around ₹954.40 lakh crore ($10 trillion). In contrast, nine recently finalized FTAs provide access to a market of approximately ₹5,726.40 lakh crore ($60 trillion), with ongoing trade negotiations set to elevate this coverage to around ₹7,158 lakh crore ($75 trillion). Highlighting the sector's economic potential, Mr. Goyal stated that the healthcare and medtech ecosystem could generate millions of jobs and catalyze vast startup activity. To boost self-reliance and technological independence, he urged the strengthening of incubation networks, intellectual property frameworks, and global innovation partnerships. The Minister pointed to government policy measures—including revised GST structures to improve healthcare affordability, 100% FDI under the automatic route, and a ₹1 lakh crore ($10.48 billion) R&D allocation—as key drivers supporting the domestic pharma industry's strategic pivot from volume to high-value output. Reinforcing the need for resilient healthcare supply chains post-pandemic, he expressed confidence that synergistic efforts across research and industry will significantly advance India’s broader Viksit Bharat 2047 goals.

Import Checks Tighten Domestic Players Get a Closer Look

A small regulatory change can sometimes tell a much bigger industry story. The government has directed Customs officers to manually verify licences, permissions and registrations before clearing imported drugs, medical devices, cosmetics and related inputs. The temporary measure comes because CDSCO documentation is not yet fully integrated with SWIFT 2.0. For investors, the important point is not simply “imports may face delays.” The bigger question is: Could tighter import compliance create a relative advantage for established Indian medical-device manufacturers? Poly Medicure Ltd.

🔥 14 BEST NICHE STOCKS WITH STRONG MOATS

🔥 14 BEST NICHE STOCKS WITH STRONG MOATS Not every great business needs to be a giant. Some of the best wealth creators operate in niche industries with high entry barriers, strong capabilities and limited competition. Here are 14 interesting niche businesses to track 👇 1. CDSL — Depository

India’s 86-Year-Old Drug Law Is Finally Being Rewritten

Imagine buying a medicine for a child and assuming one thing: the system has already checked it. Recent cough-syrup tragedies showed why that assumption cannot always be taken for granted. India’s 1940 Drugs and Cosmetics Act is now 86 years old, while the pharmaceutical industry has become far more complex. The proposed Draft Drugs, Medical Devices & Cosmetics Bill, 2026 attempts to modernise this framework. The core problem is fragmented regulation. Drug approvals sit largely with the Centre, while manufacturing licences are handled by state regulators. This creates gaps in coordination and enforcement. India has already conducted hundreds of risk-based inspections, with regulatory action against a large number of high-risk facilities. The proposed framework could bring: • Greater centralisation of manufacturing licensing • Stronger quality-control mechanisms • Clearer rules for e-pharmacies • A modern framework for medical devices • More proportionate treatment of minor procedural violations But there is a catch. States are reluctant to surrender regulatory powers, while medical-device companies argue that devices require a separate regulatory framework because engineering products cannot simply be regulated like medicines. Stocks to watch If implementation improves quality standards and favours manufacturers with strong compliance infrastructure, established Nifty 500 healthcare names could potentially be better positioned. Sun Pharma

India’s MedTech Revolution: Building a $250 Billion Global Powerhouse

India’s medical technology sector is undergoing a monumental shift toward self-reliance, transforming the country into a reliable global hub for healthcare innovation. Driven by strategic government initiatives—including the Production Linked Incentive (PLI) Scheme, PRIP Scheme, and dedicated Medical Device Parks—India has already begun indigenous manufacturing for over 50 complex medical devices. To cement international trust and curb import dependency, national efforts are actively tightening regulatory frameworks, upgrading testing infrastructure, and enforcing strict safety standards for long-term supply chain resilience. Currently valued at ₹1.42–1.52 lakh crore ($15–16 billion) and expanding by nearly 12% annually, India stands as the fourth-largest MedTech market in Asia. Driven by rapid breakthroughs in artificial intelligence, surgical robotics, connected devices, and remote diagnostics, the industry is on track to hit $30–50 billion within this decade and a projected $250 billion by 2047. This trajectory promises to significantly boost domestic manufacturing, exports, and high-skilled employment while making advanced healthcare far more affordable and accessible.

The biggest competitive advantage isn't always technology.

Sometimes, it's being written into someone else's process. A bank can't easily change its registrar from